SGLT-2 抑制剂在高伤性心肌病中改善心脏功能:一项与现实世界倾向性得分匹配的研究
Cong Ding1, Fangchao Lv2, Lin Wang2
1Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Frontiers in cardiovascular medicine
|March 2, 2026
概括
-葡萄糖共运输体2抑制剂 (SGLT-2i) 显示出对缩性心肌病 (HCM) 的治疗有希望. 这项研究发现,SGLT-2i在HCM患者中改善了腹功能和NYHA类,没有任何不良影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 增高性心肌病变 (HCM) 是一种遗传性心脏病,其特征是左心室过度增大和扩张功能障碍.
- -葡萄糖共运输体2抑制剂 (SGLT-2i) 是已确定的心力衰竭 (HF) 治疗方法,但它们在HCM中的疗效尚未得到充分研究.
研究的目的:
- 评估SGLT-2i在被诊断为HCM的患者的临床有效性.
- 评估SGLT-2i对心声回声学参数和HCM功能状态的影响.
主要方法:
- 一项回顾性分析将94名用SGLT-2i治疗的HCM患者与94名匹配的对照进行了比较.
- 主要终点包括6个月后心声测量 (septal e',E/e',IVST) 和NYHA类的变化.
- 二级终点是心力衰竭再入院,随访时间中位数为16.3个月.
主要成果:
- 在6个月后,SGLT-2i治疗导致隔膜e' (p=0.002),E/e' (p<0.001),IVST (p=0.005) 和NYHA类 (p=0.031) 的显著改善.
- 多变量分析证实了隔膜e,E/e和NYHA类的持续改善.
- 两组之间没有观察到心力衰竭再入院率的显著差异 (p=0.73).
结论:
- 在HCM患者中,SGLT-2i的使用改善了左心室透静功能和NYHA类.
- 用SGLT-2i治疗并没有增加功能障碍或低血糖的风险.
- 这些发现支持SGLT-2i在治疗HCM中的潜在治疗价值.
更多相关视频
04:24A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
12.7K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
11.1K
相关概念视频
01:30Heart Failure V: Medical Management
429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
578
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
01:29Cardiomyopathy V: Interprofessional Care
551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
677
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
677